



THE CANADIAN JOURNAL OF

# Neurological Sciences

LE JOURNAL CANADIEN DES

# Sciences Neurologiques

AN INTERNATIONAL JOURNAL / UN JOURNAL INTERNATIONAL

## EDITORIALS

- 259 Changes and Leadership at CJNS  
*Douglas Zochodne*

## REVIEW ARTICLES

- 260 Responsabilités Neuroéthiques (Version française)  
*Eric Racine, Judy Illes*
- 269 Neuroethical Responsibilities (English Version)  
*Eric Racine, Judy Illes*
- 278 Canadian Association of Neurosciences Review: Polyglutamine Expansion Neurodegenerative Diseases  
*Ray Truant, Lynn A. Raymond, Jianrun Xia, Deborah Pinchev, Anjee Burtmik, Randy Singh Atwal*

## ORIGINAL ARTICLES

- 292 Propionibacterium Acnes Infections After Cranial Neurosurgery  
*Michael E. Kelly, Daryl R. Fourney, Raphael Guzman, Venkatraman Sadanand, Robert W. Griebel, Stephen E. Sanche*
- 296 Bilateral Agenesis of the Hippocampal Dentate Gyrus in a Neurologically Normal Adult  
*Arthur W. Clark, Harvey B. Sarnat*
- 302 Rasmussen's Encephalitis in a 58-Year-Old Female: Still a Variant?  
*Gary R. W. Hunter, Jeffrey Donat, William Pryse-Phillips, Sheri Harder, Christopher A. Robinson*
- 306 Intractable Childhood Epilepsy and Maternal Fatigue  
*Mohammed M.S. Jan*
- 311 A Novel GDAP1 Mutation 439delA is Associated with Autosomal Recessive CMT Disease  
*Domna-Maria Georgiou, Paschalis Nicolaou, David Chitayat, Pantelitsa Koutsou, Riyana Babul-Hirji, Jiri Vajsar, Jillian Murphy, Kyproula Christodoulou*

## NEUROIMAGING HIGHLIGHT


- 317 Submitted by: *Lauren M. Segal, Angela Walker, Eric Marmor, Errol Stern, Mark Levental, Rafael S. Glikstein, Hyman M. Schipper*

## PEER REVIEWED LETTERS (See contents pages)


## CORRESPONDENCE (See contents pages)

## SUPPLEMENT 2

- S1 12th Biennial Canadian Neuro-Oncology Meeting. May 26-28, 2006 Abstracts



Neuroimaging Highlight



Polyglutamine Expansion

### 42nd ANNUAL CONGRESS

presented by the

**Canadian Neurological  
Sciences Federation  
(formerly CCNS)**



June 19-22, 2007  
Edmonton, Alberta

# Real accuracy. Real results.

No other radiosurgery system for non-invasive brain surgery has the accuracy, stability and efficacy of Leksell Gamma Knife®. Or the proof to back it up.

With over 2,000 peer-reviewed published articles, Leksell Gamma Knife® has an unmatched body of clinical evidence. Our accuracy is also unmatched, with a recent study demonstrating an average accuracy of 0.15 mm and a clinical accuracy (including imaging) of 0.48mm.

Read it for yourself. Get the Leksell Gamma Knife® Accuracy brochure at [www.elekta.com/proof](http://www.elekta.com/proof).





THE CANADIAN JOURNAL OF

# Neurological Sciences

LE JOURNAL CANADIEN DES

# Sciences Neurologiques

## EDITORIALS

- 259** Changes and Leadership at CJNS  
*Douglas Zochodne*

## REVIEW ARTICLES

- 260** Responsabilités Neuroéthiques (Version française)  
*Eric Racine, Judy Illes*
- 269** Neuroethical Responsibilities (English Version)  
*Eric Racine, Judy Illes*
- 278** Canadian Association of Neurosciences Review:  
Polyglutamine Expansion Neurodegenerative Diseases  
*Ray Truant, Lynn A. Raymond, Jianrun Xia, Deborah Pinchev, Anjee Burtnik, Randy Singh Atwal*

## ORIGINAL ARTICLES

- 292** Propionibacterium Acnes Infections After Cranial Neurosurgery  
*Michael E. Kelly, Daryl R. Fourney, Raphael Guzman, Venkatraman Sadanand, Robert W. Griebel, Stephen E. Sanche*
- 296** Bilateral Agenesis of the Hippocampal Dentate Gyrus in a Neurologically Normal Adult  
*Arthur W. Clark, Harvey B. Sarnat*
- 302** Rasmussen's Encephalitis in a 58-Year-Old Female: Still a Variant?  
*Gary R. W. Hunter, Jeffrey Donat, William Pryse-Phillips, Sheri Harder, Christopher A. Robinson*
- 306** Intractable Childhood Epilepsy and Maternal Fatigue  
*Mohammed M.S. Jan*
- 311** A Novel GDAP1 Mutation 439delA is Associated with Autosomal Recessive CMT Disease  
*Domna-Maria Georgiou, Paschalis Nicolaou, David Chitayat, Pantelitsa Koutsou, Riyana Babul-Hirji, Jiri Vajsar, Jillian Murphy, Kyproula Christodoulou*

## NEUROIMAGING HIGHLIGHT

- 317** Submitted by: *Lauren M. Segal, Angela Walker, Eric Marmor, Errol Stern, Mark Levental, Rafael S. Glikstein, Hyman M. Schipper*

## PEER REVIEWED LETTERS

- 320** Unilateral Hypoglossal Nerve Palsy Following the Use of the Laryngeal Mask Airway  
*Timothy S. Lo*
- 322** Occipital Condyle Fracture with Associated Hypoglossal Nerve Injury  
*Shaan Chugh, Kambiz Kamian, Bart Depreitere, Michael L. Schwartz*
- 325** Fibrous Dysplasia of the Skull Base Presenting Acutely in an Adult  
*F. Amoozegar, A. Guberman*
- 328** Sepsis from Neurofibromatosis  
*Navdeep Tangri, Shireen Sirhan, Gordon Crelinsten*
- 329** Pituitary Carcinoma with Subependymal Spread  
*Krishna Kumar, Jefferson R. Wilson, Qiuyan Li, Ryan Phillipson*

- 333** Correspondence
- 334** Books Received
- 334** Books Reviewed
- 337** Calendar of Events
- 338** Notes and Announcements
- A-5, A-6** Information for Authors
- A-25** Advertisers Index

## SUPPLEMENT 2

- S1** 12th Biennial Canadian Neuro-Oncology Meeting  
May 26-28, 2006 Abstracts



THE CANADIAN JOURNAL OF

# Neurological Sciences

LE JOURNAL CANADIEN DES

# Sciences Neurologiques

**Editor-in-Chief/Rédacteur en chef**  
Douglas W. Zochodne CALGARY, AB

**Associate Editors/Rédacteurs associés**  
J. Max Findlay EDMONTON, AB  
Michael Shevell MONTREAL, QC  
G. Bryan Young LONDON, ON

**Past Editors/Anciens rédacteurs en chef**  
James A. Sharpe TORONTO, ON  
Robert G. Lee CALGARY, AB  
Robert T. Ross WINNIPEG, MB  
(Emeritus Editor, Founding Editor)

**Editorial Board/Conseil Scientifique**  
Timothy J. Benstead HALIFAX, NS  
J. Gregory Cairncross CALGARY, AB  
Richard Desbiens QUEBEC CITY, QC  
Ian Fleetwood HALIFAX, NS  
David Fortin SHERBROOKE, QC  
Hans-Peter Hartung DUSSELDORF, GERMANY  
Alan C. Jackson KINGSTON, ON  
Jack Jhamandas EDMONTON, AB  
Daniel Keene OTTAWA, ON  
Douglas Kondziolka PITTSBURGH, PA, USA  
Terence Myles CALGARY, AB  
David Ramsay LONDON, ON  
Guy Rouleau MONTREAL, QC  
Paul Steinbok VANCOUVER, BC  
Oksana Suchowersky CALGARY, AB  
Brian Toyota VANCOUVER, BC  
Brian Weinschenker ROCHESTER, MN, USA  
Samuel Wiebe CALGARY, AB  
Elaine Wirrell CALGARY, AB

**SECTION EDITORS/CONSEIL DE RÉDACTION**

**Neuroimaging Highlight/Neuroimagerie**  
Mark Hudon CALGARY, AB  
Richard Farb

**Neuropathological Conference/Conférence sur la neuropathologie**  
David Ramsay LONDON, ON

**Book Review/Critiques de livres**  
Andrew Kirk SASKATOON, SK

**Electronic Editor/Rédacteur d'électronique**  
Daniel Keene OTTAWA, ON

**Journal Staff/Personnel de journal**  
Dan Morin, *Chief Executive Officer*  
Maggie McCallion, *Designer/Production Coordinator*  
Cindy Leschyshyn, *Editorial Coordinator*

**Publications Committee/Comité de Rédaction**  
Samuel Wiebe CALGARY, AB  
David Fortin SHERBROOKE, QC  
Asuri Prasad WINNIPEG, MB  
Richard McLachlan LONDON, ON

The official journal of: / La Revue officielle de:

The Canadian Neurological Society  
La Société Canadienne de Neurologie  
The Canadian Neurosurgical Society  
La Société Canadienne de Neurochirurgie  
The Canadian Society of Clinical Neurophysiologists  
La Société Canadienne de Neurophysiologie Clinique  
The Canadian Association of Child Neurology  
L'Association Canadienne de Neurologie Pédiatrique

The permanent secretariat for the four societies and the Canadian Congress of Neurological Sciences is at:  
Le secrétariat des quatre associations et du Congrès Canadien des Sciences Neurologiques est situé en permanence à:  
7015 Macleod Trail SW, Suite 709, Calgary AB, Canada T2H 2K6.

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate for Individuals are: C\$85 (Canada), US\$85 (USA), and US\$90 (elsewhere). Subscription rates for Institutions are: C\$95 (Canada), US\$95 (USA), and US\$100 (elsewhere). Resident, intern and student rates are available. See [www.cjns.org](http://www.cjns.org) for details. Single copies C\$24 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, P.O. Box 5456, Station A, Calgary, AB Canada T2H 1X8. Courier to: 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: [journal@cjns.org](mailto:journal@cjns.org); Website: [www.cjns.org](http://www.cjns.org)

COPYRIGHT © 2006 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under Publications Mail Agreement no: 40007777; PAP Registration no: 09824. Postage paid at Calgary, Alberta. This journal is indexed by *Abstracts on Hygiene and Communicable Diseases, Aquatic Sciences and Fisheries Abstracts, ASCA-Automatic Subject Citation Alert, Biological Abstracts, BIOBASE, BIOSIS, Chemical Abstracts Current Awareness in Biological Sciences, Current Contents (Clinical Medicine and Life Sciences), Dental Index, e-psyche, Excerpta Medica, Index Medicus, Index to Scientific Reviews, Journal Watch Neurology, Laboratory Hazards Bulletin, Leisure, Recreation and Tourism Abstracts, MEDLINE, Neurosciences Citation Index, Nutrition Abstracts and Reviews, Nutrition Research Newsletter, Pharmacoeconomics and Outcome News, PsychInfo, Psychological Abstracts, Reactions Weekly, Referativnyi Zhurnal, Review of Medical and Veterinary Mycology, Science Citation Index, Weed Abstracts.*


Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 85 \$C (non-membres au Canada); 85 \$É-U (Etats Unis) et 90 \$É-U (ailleurs); l'abonnement annuel pour les institutions est de 95 \$C (non-membres au Canada); 95 \$É-U (Etats Unis) et 100 \$É-U (ailleurs); Internes, résidents, fellows pré et post doctoral voir [www.cjns.org](http://www.cjns.org) pour détails. Copie simple: 24 \$C plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques, P.O. Box 5456, Station A, Calgary, AB Canada T2H 1X8. Par courrier: 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail [journal@cjns.org](mailto:journal@cjns.org); Website: [www.cjns.org](http://www.cjns.org)

DROITS D'AUTEUR © 2006: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Posté sous poste-publications: numéro de convention: 40007777; numéro d'enregistrement PAP 09824. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Abstracts on Hygiene and Communicable Diseases, Aquatic Sciences and Fisheries Abstracts, ASCA-Automatic Subject Citation Alert, Biological Abstracts, BIOBASE, BIOSIS, Chemical Abstracts Current Awareness in Biological Sciences, Current Contents (Clinical Medicine and Life Sciences), Dental Index, e-psyche, Excerpta Medica, Index Medicus, Index to Scientific Reviews, Journal Watch Neurology, Laboratory Hazards Bulletin, Leisure, Recreation and Tourism Abstracts, MEDLINE, Neurosciences Citation Index, Nutrition Abstracts and Reviews, Nutrition Research Newsletter, Pharmacoeconomics and Outcome News, PsychInfo, Psychological Abstracts, Reactions Weekly, Referativnyi Zhurnal, Review of Medical and Veterinary Mycology, Science Citation Index, Weed Abstracts.*

**Advertising representative/Représentant de publicité:**  
Jhoanna Del Rosario, *Corporate Development Coordinator*  
Tel (403) 229-9575 Fax (403) 229-1661  
E-mail: [journal@cjns.org](mailto:journal@cjns.org); Web Site: [www.cjns.org](http://www.cjns.org)

**Printer/Imprimeur:**  
Sundog Printing Limited, 1311 Ninth Avenue SW  
Calgary, Alberta T3C 0H9

ISSN 0317 - 1671

We acknowledge the assistance of the Government of Canada through the Publications Assistance Program towards our mailing costs. 



sanofi aventis

Because health matters

# PORTRAIT OF A FAMILY HISTORY

## HISTORY DOESN'T HAVE TO REPEAT ITSELF

### Help Reduce the Risk of CV Death

# by 26%<sup>1</sup>

( $p < 0.001$ ; 6.1% vs. 8.1%)

ALTACE 10 mg.

The proven CV risk reduction dose.<sup>1</sup>

Roger,  
History of  
angina.

Died age 57  
of MI.

Alice, History  
of diabetes and  
hypercholesterolemia.

Died age 62 of  
complications  
related to stroke.



**ALTACE 10 mg**  
ramipril

GUARDING AGAINST CV DEATH


Altace is indicated in the treatment of essential hypertension, normally when beta-blockers and diuretics are inappropriate. It may be used alone or in association with thiazide diuretics. Altace is indicated following acute myocardial infarction in clinically stable patients with signs of left ventricular dysfunction to improve survival and reduce hospitalizations for heart failure.

Altace may be used to reduce the risk of MI, stroke or CV death in patients over age 55 who are at high risk of CV events because of a history of CAD, stroke, peripheral artery disease or diabetes accompanied by at least 1 other CV risk factor such as hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking or documented microalbuminuria.

Like other ACE inhibitors, Altace is not recommended for pregnant or lactating women and should be used with caution in patients with renal insufficiency. The most frequent adverse events occurring in clinical trials with Altace monotherapy in hypertensive patients who were treated for at least 1 year ( $n=651$ ) were: headache (15.1%), dizziness (3.7%), asthenia (3.7%) and chest pain (2.0%). Discontinuation of therapy due to clinical adverse events was required in 5 patients (0.8%). In the HOPE study, the reasons for stopping treatment were cough (ramipril 7.3% vs. placebo 1.8%), hypotension/dizziness (ramipril 1.9% vs. placebo 1.5%) and edema (ramipril 0.4% vs. placebo 0.2%).

## ALTACE is the most prescribed ACEI in Canada and the ACEI most prescribed by cardiologists.\*

\*IMS Health Canada: Canadian CompuScript Audit, Moving Annual Total ending December 2005, Total Dispensed Prescriptions.



Product Monograph available to physicians and pharmacists upon request.

sanofi-aventis Canada Inc. Laval, Quebec H7L 4A8

CDN.RAM.06.02.02E

A-3

For brief prescribing information see page A-14

New indication based on the **CARDS<sup>§</sup>** Trial Results<sup>†</sup>

## Trusted Power for You and Your Patients

**LIPITOR** offers up to 50% LDL-C reduction at starting doses of 10, 20 and 40 mg<sup>1\*</sup>

\* When a >45% LDL-C reduction is required, patients may be started at 40 mg o.d.

**Power**

**AND** is indicated to reduce the risk of MI and stroke in patients with type 2 diabetes and hypertension without CHD but with other risk factors<sup>1</sup>

**Evidence**

**ONLY LIPITOR** is supported by 5 million patient-years of therapy in Canada<sup>2†</sup>

**Trust**

LIPITOR is an HMG-CoA reductase inhibitor (statin). LIPITOR is indicated as an adjunct to lifestyle changes, including diet, for the reduction of elevated total cholesterol (total-C), LDL-C, TG and apolipoprotein B (apo B) in hyperlipidemic and dyslipidemic conditions (including primary hypercholesterolemia, combined [mixed] hyperlipidemia, dysbetalipoproteinemia, hypertriglyceridemia and familial hypercholesterolemia) when response to diet and other non-pharmacological measures alone has been inadequate.

LIPITOR also raises HDL-cholesterol and therefore lowers the LDL-C/HDL-C and total-C/HDL-C ratios (Fredrickson Type IIa and IIb dyslipidemia).

LIPITOR is indicated to reduce the risk of myocardial infarction in adult hypertensive patients without clinically evident coronary heart disease, but with at least three additional risk factors for coronary heart disease such as age ≥55 years, male sex, smoking, type 2 diabetes, left ventricular hypertrophy, other specified abnormalities on ECG, microalbuminuria or proteinuria, ratio of plasma total cholesterol to HDL-cholesterol ≥6 or premature family history of coronary heart disease.

† LIPITOR is also indicated to reduce the risk of myocardial infarction and stroke in adult patients with type 2 diabetes mellitus and hypertension without clinically evident coro-

LIPITOR and with other HMG-CoA reductase inhibitors.

Patients who develop any signs or symptoms suggestive of myopathy should have their CK levels measured. LIPITOR therapy should be discontinued if markedly elevated CK levels are measured or myopathy is diagnosed or suspected.

See Prescribing Information for complete warnings, precautions, dosing and administration.

Less than 2% of patients discontinued therapy due to adverse experiences. Most common adverse effects vs. placebo occurring in patients at an incidence ≥1% were constipation (1% vs. 1%), diarrhea (1% vs. 1%), dyspepsia (1% vs. 2%), flatulence (1% vs. 2%), nausea (1% vs. 0%), headache (1% vs. 2%), pain (1% vs. <1%), myalgia (1% vs. 1%) and asthenia (1% vs. <1%). The adverse events reported in ≥1% of boys and postmenarchal girls (10-17 years of age) were abdominal pain, depression and headache.

LIPITOR is contraindicated: During pregnancy and lactation; active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal; hypersensitivity to any component of this medication.

The dosage of LIPITOR should be individualized according to the baseline LDL-C, total-C/HDL-C ratio and/or TG levels to achieve

**LIPITOR**  
atorvastatin calcium  
tablets

power you can trust™

10 mg 20 mg 40 mg 80 mg

elderly or are concomitantly being administered digoxin or CYP 3A4 inhibitors.

Liver function tests should be performed before the initiation of treatment, and periodically thereafter.

If increases in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) show evidence of progression, particularly if they rise to greater than 3 times the upper limit of normal and are persistent, the dosage should be reduced or the drug discontinued.

LIPITOR, as well as other HMG-CoA reductase inhibitors, should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease.

§ CARDS = Collaborative Atorvastatin Diabetes Study.

† A patient-year represents the total time of exposure to LIPITOR as defined by the sum of each patient's time on LIPITOR.<sup>3</sup>

Pfizer

Life is our life's work

©2006

References: 1. LIPITOR (atorvastatin calcium) Product Monograph, Pfizer Canada Inc., November 2005. 2. IMS Health,

and/or TG levels to achieve

©2006

Pfizer Canada Inc.  
Kirkland, Quebec  
H9J 2M5

PAAB

Member of  
R&D

\* TM Pfizer Ireland Pharmaceuticals  
Pfizer Canada Inc., licensee

November 2005. 3. IMS Health, IMS MIDAS™ (Standard Units: Year 1997 through to April 2005). 3. Simon Day, Dictionary for Clinical Trials, 1999, John Wiley & Sons Ltd. 137-38.

mellitus and hypertension without clinically evident coronary heart disease, but with other risk factors such as age >55 years, retinopathy, albuminuria or smoking.

Very rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with

baseline LDL-C, total-C/HDL-C the recommended target dose needed to achieve LL

Caution should be exercised in exercising hypercholesterolemic patients who

# Neuropathic Pain Scalded From Within

**NOW AVAILABLE  
on the Quebec  
formulary**

## New

# LYRICA<sup>\*</sup>

PREGABALIN

LYRICA is indicated for the management of neuropathic pain associated with<sup>1</sup>:

- Diabetic peripheral neuropathy
- Postherpetic neuralgia

## Demonstrated fast, sustained neuropathic pain relief

- Rapid neuropathic pain relief shown in patients with PHN as early as Week 1<sup>2†</sup>
- Sustained neuropathic pain relief demonstrated over 3 months<sup>3‡</sup>
- Rapid improvement in pain-related sleep interference observed in patients with PHN as of Week 1<sup>2†</sup>
- No clinically significant pharmacokinetic drug interactions reported<sup>1‡</sup>
- Simple dosing regimen<sup>1</sup>

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

The most commonly observed adverse events (twice the rate as that seen with placebo) were dose related for PHN and DPN patients in the recommended dose range of 150 mg/day to 600 mg/day: dizziness (9-37%), somnolence (6.1-24.7%), peripheral edema (6.1-16.2%) and dry mouth (1.9-14.9%).

Dosage reduction is required in patients with renal impairment as pregabalin is primarily eliminated by renal excretion.

‡ Pharmacodynamic interactions were reported with oxycodone, lorazepam, ethanol and thiazolidinedione antidiabetic agents. Please consult Prescribing Information for complete interaction information.

Please see Prescribing Information for complete Warnings and Precautions, Dosage and Administration, and patient selection criteria.

† A 13-week, multicentre, double-blind, placebo-controlled trial in 368 patients with PHN. A significant difference was shown over placebo for all doses: 150 mg/day, 300 mg/day, and 600 mg/day at week 1,  $p < 0.001$  for pain and  $p < 0.01$  for sleep.

‡ A 12-week, multicentre, randomised, double-blind, placebo-controlled study in 338 patients with neuropathic pain (DPN [n=249] or PHN [n=89]), resulting in a significant difference from placebo in the flexible dose range 150-600 mg/day ( $p \leq 0.05$ , week 2 and  $p \leq 0.01$ , weeks 3-12), and the fixed dose of 600 mg/day ( $p \leq 0.05$ , week 1 and  $p \leq 0.01$ , weeks 2-12).

For brief prescribing information see pages A-18, A-19, A-20, A-21



©2006  
Pfizer Canada Inc.  
Kirkland, Quebec  
H9J 2M5

\*TM C.P. Pharmaceuticals International C.V.  
Pfizer Canada Inc., licensee



**New**  
**LYRICA<sup>\*</sup>**  
PREGABALIN  
*Fast onset. Sustained relief.*



## Treatment for Spinal Fractures is as Individual as your Patients

### Because not all fractures are created equal.

Kyphon offers a complete family of fracture reduction instruments, each designed to address individual patient anatomy and fracture morphology.

#### KyphX® **Xpander**™ INFLATABLE BONETAMP



This standard balloon offers fracture reduction capabilities by enabling accurate balloon placement and effective inflation geometry.

#### KyphX® **Exact**™ INFLATABLE BONETAMP

Uniquely constructed to provide uni-directional balloon inflation for focused fracture reduction. This balloon is recommended for wedge or concave fractures with single-endplate involvement.




#### KyphX® **Latitude**™ CURETTE



Intended to scrape and score cancellous bone in the spine. May be used as an adjunctive device with Kyphon's fracture reduction instruments.

#### KyphX® **Elevate**™ INFLATABLE BONETAMP

Provides single-plane preferential inflation resulting in 50% greater superior/inferior profile in comparison to the medial/lateral profile. This balloon is recommended for bi-concave or wedge fractures with involvement of both endplates.



#### KyphX® **Express**™ INFLATABLE BONETAMP



Designed to treat smaller vertebral bodies and/or vertebra plana fractures.

To learn more about expanding your options for fracture reduction, call 1-877-459-7466.

Although the complication rate with kyphoplasty has been demonstrated to be low, as with most surgical procedures, there are risks associated with kyphoplasty, including serious complications. For complete information regarding indications for use, warnings, precautions, adverse events and methods of use, please reference the devices' Instructions for Use. Kyphon, KyphX and KyphX Xpander are registered trademarks of Kyphon Inc. Elevate, Exact, Express, Latitude and Ahead of the Curve are trademarks of Kyphon Inc. ©2005 Kyphon Inc. All rights reserved. 16000500-01


[www.kyphon.com](http://www.kyphon.com)

**KYPHON**  
AHEAD OF THE CURVE™

## NAME CHANGE

### Canadian Congress of Neurological Sciences to Canadian Neurological Sciences Federation

Recently our name was officially changed to the Canadian Neurological Sciences Federation to better reflect the fact that we represent a federation of four professional societies. Our official announcement and changes to our logo, website, etc. are coming shortly.



Join us  
in Edmonton, Alberta  
for the

**42nd Annual Congress**  
presented by the  
**Canadian Neurological  
Sciences Federation**

(CNSF)

June 19-22, 2007





## Betaseron®: Demonstrated long-term efficacy\*

### In a major clinical trial, Betaseron® patients' experienced:

- 31% reduction in annual exacerbation rate vs. the placebo group ( $p=0.0001$ )<sup>†‡</sup>
- Significant reduction in moderate or severe attacks per year vs. the placebo group ( $p=0.001$ )<sup>§</sup>
- Significantly fewer lesions on MRI ( $p=0.0001$ )<sup>||\*\*</sup>

16-year study ongoing<sup>2</sup>

### The MS Pathways™ support program offers Betaseron® patients a caring and convenient approach to MS therapy – right from the start

- Multilingual nurse telephone support line for personalized assistance
- In-home Betaseron® injection training program
- Medical travel assistance and related services

\*Double-blind, multi-clinic (11 site) randomized, parallel, placebo-controlled clinical investigation, two-year duration, subjects received 1.6 MIU Betaseron® (n=125), 8 MIU Betaseron® (n=124) or placebo (n=123).

†Treated with 8 MIU Betaseron®, self-administered, every other day.

‡0.9 vs. 1.31

§Mean of 19.5 moderate or severe exacerbation days per patient vs. 41.1 days

\*\*0.9% decrease in MRI lesion area vs. 21.4% increase in placebo group



Act early. Act strong.

BETASERON® (interferon beta-1b) is indicated for the reduction of the frequency of clinical exacerbations in ambulatory patients with relapsing-remitting multiple sclerosis (RRMS) and for the slowing of the progression in disability and the reduction of the frequency of clinical exacerbations in patients with secondary-progressive multiple sclerosis (SPMS). The safety and efficacy of BETASERON® in primary-progressive MS (PPMS) have not been evaluated. Efficacy of treatment for longer than two years has not been substantially demonstrated in RRMS. The most common side effects related to BETASERON® in patients with RRMS are: flu-like symptom complex (76%); fever (59%); chills (46%); injection site reactions (85%); myalgia (44%); asthenia (49%) and malaise (15%).

For complete warnings and precautions, please refer to the product monograph available to healthcare professionals upon request.

References: 1. Betaseron® Product Monograph, June 2004. 2. Data on file. Berlex Canada Inc.

# ROXON

# CADWELL

EMG

EP

EEG

PSG

Ambulatory EEG


IOM



Evoke your potential  
Évoquez votre potentiel

**Thank you for visiting our booth at the CCNS !  
Merci d'avoir visité notre kiosque au CCNS !**





## Betaseron® Efficacité à long terme éprouvée\*

### Durant une étude clinique d'importance, les patients' prenant Betaseron ont présenté :

- une réduction de 31% de leur taux annuel de poussées par rapport aux patients du groupe placebo ( $p = 0,0001$ )<sup>†</sup>
- une diminution significative du nombre annuel de leurs poussées modérées ou graves par rapport aux patients du groupe placebo ( $p = 0,0001$ )<sup>‡</sup>
- un nombre significativement moindre de lésions observables à l'IRM ( $p = 0,0001$ )<sup>§</sup>

Étude en cours depuis 16 ans<sup>2</sup>

### SEP LeParcours offre aux patients atteints de SEP prenant Betaseron un programme de soutien à visage humain et une démarche thérapeutique pratique – dès le début

- Ligne d'aide où du personnel infirmier multilingue offre un service personnalisé
- Programme de formation à domicile sur l'injection de Betaseron
- Assistance médicale en voyage et services associés

\* Étude clinique multicentrique (11 centres) parallèle, randomisée, à double insu et contrôlée par placebo, d'une durée de deux ans, menée auprès de patients recevant 1,6 MUI de Betaseron (n = 125), 8 MUI de Betaseron (n = 124) ou un placebo (n = 123).

† Traités par 8 MUI de Betaseron auto-administrés tous les deux jours

‡ 0,9 vs 1,31

§ Moyenne de 19,5 jours de poussées modérées ou graves par patient vs 41,1 jours

\*\* Diminution de 0,9% de l'étendue des lésions observables à l'IRM vs une augmentation de 21,4% dans le groupe placebo



**BETASERON®**  
INTERFÉRON BÉTA-1b

Agir tôt. Agir en force.

BETASERON (interféron bêta-1b) est indiqué pour réduire la fréquence des poussées cliniques chez les patients ambulatoires atteints de sclérose en plaques rémittente (SEP) et pour ralentir la progression de l'incapacité et réduire la fréquence des poussées cliniques chez les patients atteints de SEP progressive-secondaire. L'efficacité et l'innocuité de BETASERON dans la SEP progressive-primaire n'ont pas été évaluées. On ne dispose pas de données probantes sur l'efficacité du traitement de la SEP rémittente au-delà de deux ans. Chez les patients atteints de SEP rémittente, les effets indésirables les plus courants liés à l'utilisation de BETASERON sont : syndrome pseudo-grippal (76 %) ; fièvre (59 %) ; frissons (46 %) ; réactions au point d'injection (85 %) ; myalgie (44 %) ; asthénie (49 %) et malaise (15 %).

Pour plus de renseignements sur les mises en garde et les précautions, veuillez consulter la monographie du produit fournie sur demande aux professionnels de la santé.  
Références : 1. Monographie de Betaseron, juin 2004. 2. Données internes. Berlex Canada inc.